Symbols

AMLX

Amylyx·NASDAQ

--(--)

AMLX fundamentals

AMLX Q4 2025 Earnings

Amylyx (AMLX) released its earnings on Mar 3, 2026: revenue was 0 (YoY +100.00%), beat estimates; EPS was -0.3 (YoY +45.45%), beat estimates.

Revenue / YoY

+100.00%

EPS / YoY

-0.3

+45.45%

Report date

Mar 3, 2026

AMLX Earnings Call Summary for Q4,2025

Avexitide Trial Milestone: LUCIDITY recruitment complete, targeting 2027 launch with 160,000 U.S. PBH patients estimated.
Financial Strength: $317 million cash runway into 2028, 8% YoY expense decline.
Pipeline Expansion: AMX0318 nominated for long-acting GLP-1 antagonist, IND filing in 2027.
Market Validation: Clinician and patient feedback confirm PBH as severe, unmet need.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Amylyx (AMLX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Amylyx (AMLX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Amylyx (AMLX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Amylyx (AMLX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown